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Abstract 
 
Objective 
Adaptive trial design was developed initially for oncology to improve trial efficiency. 
If optimised for Rheumatology, it may improve trial efficiency by reducing sample 
size and time.  
 
Methods 
A systematic review assessed current design of phase II II clinical trials in Rheumatoid 
Arthritis regulatory requirements for adaptive design was also reviewed. .  
 
Results 
56 trials were reviewed. Most trials had 4 groups (1 control and 3 intervention), with 
an average group size of 34 patients. ACR20 measured at 16 weeks was the most 
commonly used primary endpoint. Regulatory review established a list of 
methodology issues. 
 
Conclusion 
The next step is to undertake a systematic review of adaptive designs utilised in early 
phase trials in non-Rrheumatic conditions and produce a statistical analysis plan for 
assessing outcome measures for interim analysis.  
 Introduction 
Randomized controlled/clinical trials are the gold standard in evidence-based 
ŵediĐiŶe. Hoǁeǀer, aŶ editorial iŶ the JourŶal of Rheuŵatology, ͞Arthritis CliŶiĐal 
Trial at a Crossroad͟ iŶ ϮϬϭ5 ďy Pope et al highlighted the ͞ĐritiĐal state of 
rheuŵatology ĐliŶiĐal trials͟. [1] Clinical Trialists struggled to recruit patients because 
of inefficient trial design, funding and regulatory requirements. Recruiting patients 
from countries with less access to expensive treatment has become more common 
but increases the risk of higher placebo response. This is a common issue and not 
unique to Rheumatology. Clinical trials are resource intensive, in terms of time, 
personnel, finance and available patient pool. Some of these obstacles could be 
mitigated by using adaptive trial designs, which have been developed to improve 
clinical trial efficiency. Adaptive clinical trial designs have been increasingly used in 
Oncological and Cardiovascular diseases. [2-6[add ref] Both the U.S. Food and Drug 
Administration (FDA) and European Medicine Agency (EMA) accept adaptive clinical 
trial designs, issuing guidance on aspects that require special consideration. [72, 83] 
 
An adaptive clinical trial is defined as a design that allows modifications to the trial, 
and/or statistical procedures of the trial, after its initiation without undermining its 
validity and integrity. [94] The purpose is to make clinical trials more flexible and 
efficient. However, modifications and adaptations should be planned prospectively 
and based on analyses of interim data collected at pre-planned timepoints within the 
study, with or without formal statistical hypothesis testing in an unblinded manner. 
[105] 
 Adaptive clinical trial designs are attractive and promising as ineffective doses or 
treatments may be dropped early, and a larger numberthe proportions of patients 
allocated to therapeutically promising in treatment arms can be adjusted based on 
interim analyses. Moreover, these designs allow for tailored dose titration of 
individual agents based on observed results so that the optimal dose may be more 
rapidly and efficiently identified. This will also reduce the number of patients 
receiving subtherapeutic doses in early phase II trials. In large intervention trials, 
such as surgery, non-promising therapies, can be terminated early. If the statistical 
and methodological principles of adaptive clinical trial designs can be optimized in 
Rheumatic Diseases, it will address some of the issues highlighted by Pope et al. by 
improving clinical trial efficiency, reducing sample size, exposure to inadequate 
doses, time and cost, to thewhich will benefit of funders, researchers and patients. 
 
Adaptive Trial Design Steering Committee 
Members of the steering committee of the adaptive trial design SIG include 
Rheumatologists, clinical trialists, epidemiologists, and statisticians from academia 
and industry. Regular teleconferences have been held to discuss objectives, research 
plan and report progress. 
 
Adaptive clinical trial design is novel to Rheumatology, so the initial focus of the SIG 
will be in Rheumatoid Arthritis as RA OMERACT core outcome set already exists with 
established composite outcome measures such as American College of 
Rheumatology (ACR) responses criteria and Disease Activity Score (DAS), which are 
widely used as primary endpoint in clinical trials. For adaptive design trials, it is 
important to establish the clinical relevance and discriminatory performance of 
these outcome measures at earlier, relevant interim timepoints in particularly their 
ability to predict final outcome to select the best outcome measure for interim 
analysis. Rheumatoid arthritis (RA) will be the initial focus of the SIG since OMERACT 
core outcome measures are the established gold standard and are widely used in 
clinical trials. 
 
The key objectives of the adaptive trial design SIG are: 
 
1. Define optimal study design(s) including determination of the best outcome 
measures, [116] time point and sample size for interim statistical analysis 
2. Identify potential barriers and the methodological issues toin implementation 
of adaptive trial design in practice and address issues raised by FDA and EMA 
in RA 
3. Explore the types ofpotential biases that could occur related to inference 
from adaptive trial designs in Rrheumatology 
4. Explore how adaptive trial designs may be applied in different phases and 
types of clinical trials (e.g. phase I-IV drug development trials, head-to-head 
comparison trials, pragmatic strategy trials).  
 
Method 
First, a systematic review of early phase clinical trials in RA was conducted to 
establish current practice. Adaptive trial design will need to be more efficient that 
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these standards for it to be adopted. Second, a review of regulatory requirements to 
identify key methodological issues that should be addressed.   
1. Systematic review of early phase clinical trials in RA 
We conducted a systematic review that included 56 early phase II trials in RA and 
found only one trial with an adaptive design [12]. Most phase II trials in RA had 4 
groups (1 control and 3 intervention), and an average sample size for each group of 
34 patients. ACR20 measured at 16 weeks was the most commonly used primary 
endpoint. The search also identified a statistical simulation study suggesting that 
adaptive designs can be applied to early phase trials in RA. This systematic review 
identified the typical study design of phase II trials in RA including the number of 
intervention groups, sample sizes and primary endpoint. Adaptive trial design would 
need to demonstrate superior efficiency for it to be adopted for RA. 
 
2. Review Regulatory Requirements  
Both the Food and Drug Administration (FDA) in the US and European Medicine 
Agency (EMA) in principle accept adaptive design trials. However, they have also 
highlighted methodological issues, which will be addressed by the SIG.  
These include:  
 
 dissemination of interim results, especially if not fully blinded or incorporate 
some subjective element / analyst access to unblinded interim results and 
how they may influence investigators managing the trial (who must remain 
unequivocally objective), i.e. operational bias; 
Formatted: Numbered + Level: 1 + Numbering Style: 1,
2, 3, … + Start at: 1 + Alignment: Left + Aligned at:  0.63
cm + Indent at:  1.27 cm
Formatted: Numbered + Level: 1 + Numbering Style: 1,
2, 3, … + Start at: 1 + Alignment: Left + Aligned at:  0.63
cm + Indent at:  1.27 cm
 define the mMinimum sample size or number of included participants that 
willould be required for have to reach an interim analysis time point for 
decisions to adjustapt protocola study; 
 define the risk of results based on p-values alone; 
 control of the type I error rate; 
 interpretation of study results when the study design has changed as a result 
of interim analyses; 
 rejection of a global null hypothesis across all stages, which may not be 
sufficient or methodologically sound; 
 involvement of sponsor personnel in interim decision making; 
 differential population for recruitment before and after modification, which 
will affect treatment effect; 
 making hypothesis claims from results of interim analyses; 
 interim analyses/adaptation choices provide multiple opportunities to show a 
successful treatment effect (with greater likelihood of doing so than if no 
such analyses existed), thus introducing inherent multiplicity bias; 
 the potential to select a modification as a result of an interim analysis that, 
by random chance, is more favourable than the true value, thus creating bias 
that will lead to an overestimate of the true treatment effect; 
 limiting the opportunity to reflect on the data, including safety issues, and 
thus limiting the design of future well-thought-through research; 
 an increase in pressure to make assumptions, even when only limited prior 
information exists; 
 exploratory adaptive design study flaws, which could lead to sub-therapeutic 
dose selection in subsequent (adequate and well-controlled) trials; 
 
Research Plan 
After several iterations, the steering committee have decided on two work packages 
and discussed options for a third work package. 
 
Work Package 1: Optimal design of phase II adaptive trial designs in RA 
Systematic review found that ACR20 was the most commonly used primary outcome 
measured in early phase clinical trials. However, a continuous variable, such as 
DAS28, SDAI or CDAI, may perform better for interim analyses. Primary outcome and 
the outcome for interim analyses do not need to be the same. However, if different, 
time effect and correlation between these outcome measures needs to be 
examined. Some studies have shown that response at week 4 may be predictive of 
response at 3 months suggesting that this should be assessed as a potential first time 
point for interim analysis. A statistical simulation/analysis plan is being developed to 
assess the discriminatory performance of outcome measures at timepoints, week 4, 
8 and 12. 
 
Work Package 2: A systematic review of adaptive designs utilised in early phase 
trials in other conditions 
In accordance with OMERACT Technical Advisory Group recommendations, [137] the 
SIG will undertake a systematic review of adaptive trial designs in early phase clinical 
trials beyond musculoskeletal conditions. A preliminary search found a majority of 
these trials in oncology and cardiovascular diseases. 
 
Options for Work Package 3 
Several options for work package 3 were considered, these included: 
 develop/identify best composite outcome measures for clinical trials 
 safety and high-risk patients 
 potential use of adaptive designs in phase III and IV trials 
 
Potential Limitations  Formatted: Font: Bold
One potential limitation for adaptive design is change in regulatory requirement for 
clinical trials in Rheumatology e.g. time for escape therapy, placebo control versus 
active controls. The SIG will continue to review and update research agenda to 
address these issues. 
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